Press Releases

Jul 27, 2021

Jul 13, 2021

Heat Biologics enters into Research License Agreement for ProBioGen's Transposase System and Suspension HEK293 Cell Line

Jun 22, 2021

ProBioGen and LAVA Therapeutics N.V. sign Agreement for Cell Line Development for Manufacturing of a Novel Bispecific

Jun 09, 2021

City of Hope takes a Commercial Product License to use ProBioGen’s AGE1.CR® Vaccine Manufacturing Platform

May 27, 2021

ProBioGen and Minapharm Pharmaceuticals incorporate MiGenTra GmbH – A Healthcare Transforming Medicines Company

May 27, 2021

ProBioGen und Minapharm Pharmaceuticals gründen die MiGenTra GmbH mit dem Ziel, das Gesundheitswesen zu verändern

Apr 26, 2021

Asher Biotherapeutics contracts ProBioGen to develop and manufacture their Lead Candidate

Apr 15, 2021

Nouscom activates Commercial Product License for ProBioGen’s proprietary Vaccine Production Cell Line AGE1.CR.pIX®

Mar 24, 2021

ProBioGen enters into Agreement with Nobelpharma for Manufacturing Process Development of their Vaccine Project

Mar 17, 2021

ProBioGen licenses GlymaxX® Technology to Sanofi

Page 1 of 9

Press Releases

ValenzaBio partners with ProBioGen to maximize cell line productivity and licenses GlymaxX®

Heat Biologics enters into Research License Agreement for ProBioGen's Transposase System and Suspension HEK293 Cell Line

ProBioGen and LAVA Therapeutics N.V. sign Agreement for Cell Line Development for Manufacturing of a Novel Bispecific

City of Hope takes a Commercial Product License to use ProBioGen’s AGE1.CR® Vaccine Manufacturing Platform

ProBioGen and Minapharm Pharmaceuticals incorporate MiGenTra GmbH – A Healthcare Transforming Medicines Company

ProBioGen und Minapharm Pharmaceuticals gründen die MiGenTra GmbH mit dem Ziel, das Gesundheitswesen zu verändern

Asher Biotherapeutics contracts ProBioGen to develop and manufacture their Lead Candidate

Nouscom activates Commercial Product License for ProBioGen’s proprietary Vaccine Production Cell Line AGE1.CR.pIX®

ProBioGen enters into Agreement with Nobelpharma for Manufacturing Process Development of their Vaccine Project

ProBioGen licenses GlymaxX® Technology to Sanofi